Please login to the form below

Not currently logged in
Email:
Password:

tofacitinib

This page shows the latest tofacitinib news and features for those working in and with pharma, biotech and healthcare.

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m

s Xeljanz (tofacitinib), Incyte/Eli Lilly’s Olumiant (baricitinib) and AbbVie’s upadacitinib.

Latest news

More from news
Approximately 12 fully matching, plus 61 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics